Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

APP Pharmaceuticals to immediately begin marketing Anastrozole tablets in the U.S., after the U.S. Food and Drug Administration granted approval.

Fresenius Kabi Pharmaceuticals Holding, Inc., announced that APP Pharmaceuticals will immediately begin marketing Anastrozole tablets in the U.S., after the U.S. Food and Drug Administration granted approval to market the breast cancer treatment medication to Fresenius Kabi Oncology Limited. APP Pharmaceuticals and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. Anastrozole is therapeutically equivalent to the reference-listed drug Arimidex, which is currently marketed by the innovator AstraZeneca.

APP will market Anastrozole in 1 mg tablets. According to IMS data, 2009 sales of the branded product in the United States were approximately $916.8 million, with approximately 105 million tablets sold annually.

"The approval of Anastrozole further expands APP's product portfolio in the strategically important Oncology segment," said John Ducker, president and chief executive officer of APP Pharmaceuticals. "We are delighted to be able to offer this important oral medication to new customers in the retail pharmacy channel."

Source: APP Pharmaceuticals, Inc